Sponsor
Janssen-Cilag
111 PBAC submissions on file, active 2005–2025. 76% have been recommended.
Submissions
111
2005 → 2025
Win rate
76 %
84 recommended of 111 bucketable
Drugs
35 · 32 listed
unique molecules submitted
PBS spend captured
$706M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 24 Haematology 23 Gastroenterology 12 Mental health 10 Rheumatology 8 Neurology 8 Dermatology 6 Hepatology 6 Infectious disease 3 Immunology 3
Activity by year 2005 (2) · 2006 (8) · 2007 (5) · 2008 (2) · 2009 (2) · 2010 (2) · 2011 (6) · 2012 (8) · 2013 (2) · 2014 (6) · 2015 (10) · 2016 (7) · 2017 (8) · 2018 (4) · 2019 (5) · 2020 (6) · 2021 (8) · 2022 (7) · 2023 (3) · 2024 (6) · 2025 (4)
Rejection patterns
Across 24 Not recommended decisions on file.
3× unacceptably high incremental cost-effectiveness ratio2× potential for extended use beyond disease progression2× uncertainty regarding the clinical place in therapy2× uncertain cost-effectiveness1× Uncertain overall survival benefit (did not meet pre-specified statistical significance criteria at O'Brien-Fleming boundary)Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.